A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)
      QxMD      Google Scholar   
Citation:
Am J Hematol vol 96 (12) 1595-1603
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
2388   3755   3794  
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Celgene/BMS  
Grants:
U10CA180821, U10CA180882, UG1CA233191, UG1CA233290, UG1CA233331, UG1CA233373  
Corr. Author:
 
Authors:
                         
Networks:
LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-NY158, NC002, OH008   
Study
Alliance-A061202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords: